Document is current
Any future updates will be listed below
-
Authors
Liu, Xiaoguang https://orcid.org/0000-0001-6977-5128
Nie, Litong https://orcid.org/0000-0002-0326-4517
Zhang, Yilei https://orcid.org/0000-0003-1407-0301
Yan, Yuelong https://orcid.org/0000-0001-8495-6445
Wang, Chao
Colic, Medina https://orcid.org/0000-0003-1442-1589
Olszewski, Kellen
Horbath, Amber
Chen, Xiong
Lei, Guang https://orcid.org/0000-0002-3282-0666
Mao, Chao
Wu, Shiqi
Zhuang, Li
Poyurovsky, Masha V.
James You, M.
Hart, Traver
Billadeau, Daniel D.
Chen, Junjie https://orcid.org/0000-0002-1493-2189
Gan, Boyi https://orcid.org/0000-0001-8884-6040
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R35GM130119)
Foundation for the National Institutes of Health (R01DK107733)
Foundation for the National Institutes of Health (R01CA244144)
Foundation for the National Institutes of Health (R01CA247992)
- License Information
-
More Information
Article History
Received: 16 March 2022
Accepted: 12 January 2023
First Online: 6 February 2023
Competing interests
: B.G. reports receiving consultation fees from Guidepoint Global, Cambridge Solutions and NGM Bio, and is an inventor with patent applications involving targeting ferroptosis in cancer therapy. K.O. is a full-time employee of the Barer Institute and a former full-time employee of Kadmon Corporation. M.V.P. is a full-time employee of Kadmon Corporation, a Sanofi Company. The remaining authors declare no competing interests.
